Neuland Laboratories

Neuland Laboratories Equity

The The Equity of Neuland Laboratories (NEULANDLAB.NS) as of Oct 28, 2026 is 18.74 B INR. In the previous year, The Equity was 15.25 B INR — a change of 22.93% (higher).

Equity

18.74 BINR

YoY

22.93%

Last updated:

In 2026, Neuland Laboratories's equity was 18.74 B INR, a 22.93% increase from the 15.25 B INR equity in the previous year.

The Neuland Laboratories Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
6.99 B INR
Jan 1, 2020
7.10 B INR
Jan 1, 2021
7.86 B INR
Jan 1, 2022
8.41 B INR
Jan 1, 2023
9.94 B INR
Jan 1, 2024
12.83 B INR
Jan 1, 2025
15.25 B INR
Jan 1, 2026
18.74 B INR
The Neuland Laboratories Equity history
YEAREquityYoY
18.74 BINR+22.93%
15.25 BINR+18.87%
12.83 BINR+29.03%
9.94 BINR+18.27%
8.41 BINR+6.87%
7.86 BINR+10.78%
7.10 BINR+1.52%
6.99 BINR+25.31%
5.58 BINR+2.28%
5.46 BINR+192.34%
1.87 BINR+15.65%
1.61 BINR+30.16%
1.24 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Neuland Laboratories's Equity

Neuland Laboratories's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Neuland Laboratories's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Neuland Laboratories's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Neuland Laboratories's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Neuland Laboratories’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Neuland Laboratories stock

The Equity of Neuland Laboratories is 18.74 B INR in 2026.

The Equity of Neuland Laboratories changed from 15.25 B INR to 18.74 B INR, representing a 22.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Neuland Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Neuland Laboratories

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Neuland Laboratories